Study of vaccine for triple-negative breast cancer moves into next phase
Click Here to Manage Email Alerts
Researchers at Cleveland Clinic intend to expand their study of a novel vaccine designed to prevent triple-negative breast cancer.
An ongoing phase 1A clinical trial — expected to conclude in the fourth quarter of this year — is investigating the vaccine for patients who completed treatment for early-stage, triple-negative breast cancer within the past 3 years and remain tumor free but are at high risk for recurrence.
Investigators now plan a phase 1B trial in partnership with Anixa Biosciences to evaluate the vaccine for cancer-free individuals at high risk for breast cancer who opted to voluntarily undergo prophylactic mastectomy to reduce their risk. Researchers will assess immune response and safety outcomes.
Healio spoke with principal investigator G. Thomas Budd, MD, professor of medicine and breast oncology specialist at Cleveland Clinic, about how the study will be conducted, what researchers will assess and the potential implications of the findings.
Collapse
Healio Interviews
Click Here to Manage Email Alerts